首页> 外文期刊>Hepato-gastroenterology. >Does resection of primary lesions show survival benefit for stage IV colorectal cancer patients with unresectable metastases?
【24h】

Does resection of primary lesions show survival benefit for stage IV colorectal cancer patients with unresectable metastases?

机译:原发灶切除对IV期不能切除的大肠癌患者是否显示生存获益?

获取原文
获取原文并翻译 | 示例
       

摘要

Background/Aims: The aims of the current retrospective cohort study were to compare OS of the primary resection (R-g) and the non-resection group (NR-g) after 2005. Methodology: Ninety-five patients with stage IV colorectal cancer with unresectable distant metastases were divided into 2 groups; R-g; 37 and NR-g; 58. Results: The only significant difference in clinical factors between the 2 was RO resection rate (p = 0.007). The MST in R-g was superior to that in NR-g, 30.7 vs. 21.9 months (p - 0.031). After excluding the patients that underwent RO resection, there was no difference in OS between the 2; however, the MST was 28.6 months in R-g and 17.1 months in NR-g. Conclusions: The advantage of resection of the primary is still unclear and a well-designed randomized Phase III study is expected. However, the current results suggest that resection of the primary lesion before intensive chemotherapy had some benefit for prognosis.
机译:背景/目的:本项回顾性队列研究的目的是比较2005年以后的初次切除术(Rg)和非切除术组(NR-g)的OS。方法:九十五例IV期结直肠癌患者无法切除远处转移分为两组。 R-g; 37和NR-g; 58.结果:两者之间临床因素的唯一显着差异是RO切除率(p = 0.007)。 R-g中的MST优于NR-g中的MST,分别为30.7和21.9个月(p-0.031)。排除接受RO切除的患者后,两者之间的OS无差异。但是,R-g的MST为28.6个月,NR-g的MST为17.1个月。结论:切除原发灶的优势仍不清楚,并且预期设计良好的随机III期研究。然而,目前的结果表明,在强化化疗之前切除原发灶对预后有一定益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号